Results 281 to 290 of about 363,022 (358)

The lost chord: Microchimerism [PDF]

open access: yes, 1996
Demetris, AJ   +5 more
core  

Neuronal differentiation and tissue engineering strategies for central neurous system injury repair

open access: yesBMEMat, EarlyView.
This review outlines tissue engineering advances for central nervous system (CNS) injury treatment, focusing on three core components: seed cells, inductive factors, and scaffold materials, with evaluation of their respective strengths and limitations. Tissue engineering for CNS injury repair.
Zhuqing Xia   +9 more
wiley   +1 more source

Impact of early palliative care intervention in autologous bone marrow transplantation: feasibility of a multicentric study. [PDF]

open access: yesBMC Palliat Care
Argüello-Marina M   +9 more
europepmc   +1 more source

Biomaterial design strategies for enhancing mitochondrial transplantation therapy

open access: yesBMEMat, EarlyView.
Biomaterials to facilitate mitochondrial transplantation therapy: biomaterials as barriers to protect mitochondria from pathophysiological microenvironments, like osmotic stress caused by the excessive concentration of calcium ion, reactive oxygen species, and advanced glycation end products; biomaterials integrating with biochemical cues to improve ...
Shaoyang Kang   +12 more
wiley   +1 more source

Mucoadhesive Polyvinyl Alcohol Film Containing Fridericia chica Extract for Mucositis Treatment: Pharmacological Evaluation and Active Compounds Release

open access: yesChemistry &Biodiversity, EarlyView.
ABSTRACT Oral mucositis is a frequent and painful complication of cancer therapy with limited effective options. This study evaluated a mucoadhesive polyvinyl alcohol (PVA) film containing 2.5% Fridericia chica extract as a novel strategy. The formulation was characterized for antioxidant activity, phenolic and flavonoid content, and reactive species ...
Ilza Maria de Oliveira Sousa   +12 more
wiley   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy